Anti-CD19 ADC Linker Design for Stable Targeted Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved antibody-drug conjugates that target CD19, as mouse-derived antibodies are immunogenic in humans and humanized antibodies may also be immunogenic, and existing linkers in ADCs are unstable, leading to premature drug dissociation before reaching target cells.
Innovation Solution
Development of antibody-drug conjugates comprising monoclonal antibodies and antigen-binding fragments that specifically bind to human CD19, with cleavable linkers that include branched structures and polyethylene glycol units, allowing site-specific attachment of active agents and enabling targeted drug release within cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mouse-derived or humanized antibodies are used to target CD19, then the antibody can bind to human CD19, but the antibody becomes immunogenic in humans
Solution Approach 1:
The patent changes the antibody source from mouse or humanized to fully human monoclonal antibodies, altering the biological parameter of origin to eliminate immunogenicity while maintaining CD19 binding specificity
Solution Approach 2:
The patent creates fully human antibodies that copy the structural and functional characteristics of human immunology, allowing the antibody to be produced by human B cells and thus avoiding foreign immune recognition
2Ease of manufacture
If conventional linkers are used in ADCs, then the drug can be attached to the antibody, but the linker is unstable and causes premature drug dissociation
Solution Approach 1:
The patent employs composite linker structures combining multiple functional units including cleavable linkers with specific chemical moieties (e.g., disulfide bonds, hydrazone bonds) and stabilizing elements (e.g., PEG chains, aromatic rings) to achieve both attachability and stability
Solution Approach 2:
The patent designs linkers with dynamic properties that allow stable attachment under circulation conditions but enable controlled cleavage and drug release under specific cellular conditions (e.g., reduced glutathione levels, lysosomal enzymes), transforming the linker from static to conditionally dynamic
3Reliability
If ADCs are designed to target CD19, then selective apoptosis can be triggered, but off-target effects occur due to immunogenicity and instability
Solution Approach 1:
The patent converts potential harmful off-target effects into beneficial selective toxicity by using fully human antibodies that avoid immunogenicity and stable linkers that prevent premature release, ensuring the toxic payload is released only at the target CD19+ cancer cell
Data Source
AI summary
The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-CD19 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD19, as well as methods of making and using these anti-CD19 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.